News|Articles|September 15, 2024
Targeted Pulse Quiz: September 15
Author(s)Morgan Bayer
Fact checked by: Tony Berberabe, MPH
Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.
Advertisement
Ready for the challenge? Let’s begin!
Question 1 of 4: What designation did IBI363 receive from the FDA?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Adjuvant Belzutifan Plus Pembro for Kidney Cancer
2
Selinexor Plus Ruxolitinib Improves Spleen Responses, Shows OS Signal in Frontline Myelofibrosis
3
Dr Hamilton on Tucatinib Maintenance Efficacy in HER2+ Breast Cancer
4
KLN-1010 In Vivo CAR Achieves 100% MRD Negativity in R/R Myeloma
5



































